Conclusions: There was no statistically significant difference between the 2 groups in terms of ages, and magnetic resonance imaging findings, but the patients had a significant difference (P <.05) in sex, the course of disease and Expanded Disability Status Scale (EDSS) scores after drug treatment. Patients with AQP4-IgG (À) are likely to have a better prognosis and a favorable monophasic course.
Introduction
Neuromyelitis optica spectrum disorders (NMOSD; also known as Devic's disease) is a rare but serious autoimmune-related demyelinating disease of the central nervous system (CNS) that mainly affects the optic nerves and spinal cord with high recurrence rate, and usually misdiagnosed as multiple sclerosis (MS) or acute disseminated encephalomyelitis (ADEM). [1, 2] This disease has been described for a century or more before the discovery of the highly specific autoantigen of immunoglobulin G (IgG) antibodies targeting aquaporin-4 (AQP4) which regulates water homeostasis. [3] [4] [5] It has a striking female preponderance of 9:1, of which 80% to 90% have relapsing course, and 10% to 20% patients have monophasic course. [3] [4] [5] Previous studies have demonstrated the association between NMOSD and the presence of AQP4-IgG, but the possible different clinical features in patients with seropositive or seronegative NMOSD are not well defined. In this study, we divided patients with NMOSD into AQP4-IgG positive (+) and AQP4-IgG negative (À) groups by the serologic test and made a comparative analysis of them to improve the clinical recognition for physicians.
Methods

Patients
This study was carried out in People's Hospital of Zhengzhou University. We retrospectively reviewed the electronic medical records of 95 patients from September 2015 to November 2016. All patients met the diagnosis of NMOSD according to the international consensus diagnostic criteria described as below. Patients were divided into AQP4-IgG (+) and AQP4-IgG (À) groups. To compare the disorders of the 2 groups, demographic data, clinical information, laboratory studies, image findings, drug treatment, and clinical efficacy, and the score of Expanded Disability Status Scale (EDSS) were carefully reviewed by 3 experienced investigators to ensure accurate diagnosis.
Laboratory test
Serology tests were carried out before treatment, including the detection of AQP4-IgG antibody, thyroid hormone determinations, extractable nuclear antigen (ENA) autoantibodies or more.
Magnetic resonance imaging (MRI)
Brain and spinal cord MRI were performed using a uniform protocol, including T1-weighted images, T2-weighted images, sagital T1-weighted, and fluid-attenuated inversion recovery (FLAIR) images.
Inclusion/exclusion criteria for NMOSD
Patients must meet the diagnosis of NMOSD according to the international consensus diagnostic criteria. [6] Patients with incomplete clinical data, uncertain diagnosis, critical illness, mortality, or missing follow-up data were excluded.
Statistics
All data were analyzed using IBM SPSS Statistics Base 22.0. Categorical data were compared by the Chi-square test. The Mann-Whitney U test and t test analysis were used when appropriate. Quantitative data were expressed using median (range) or mean ± standard deviation (SD). Using Shapiro-Wilk test to verify its normal distribution, if passing, statistical significance was considered as P <.05.
Results
Demographic characteristics of the patients
Of the 95 patients who were initially diagnosed with NMOSD, 28 patients were later excluded. Among the 67 inclusions, 49 (73.1%, male/female: 3/46, mean age: 40.5 ± 16.7) are seropositive, and 18 (26.9%, male/female: 8/10, mean age: 38.5 ± 18.6) are seronegative (Table 1 ). There is no significant difference in age between the AQP4-IgG (+) patients and the AQP4-IgG (À) patients (P = .68 >.05) ( Table 1) . Other initial symptoms include extremity weakness (n = 21), backache (n = 5), neck pain (n = 2), upper limb pain (n = 1), dizziness (n = 3), hiccup (n = 1), and diplopia (n = 2). In addition, nonspecific symptoms including dysphagia, ataxia and autonomic dysfunction were also found in several patients. Although it seems that motor symptoms were more common in the AQP4-IgG (À) group, there was no significant difference in onset of optic neuritis between them (Table 1 ). (Table 1) . The characteristic MRI manifestation in the AQP4-IgG(+) patients showed in Figure 1 . The MRI manifestation in the AQP4-IgG (À) patients showed in Figure 2 .
Clinical presentations
MRI findings
Baseline rates of comorbidities in NMOSD
18 cases were complicated with suspicious autoimmune diseases, including autoimmune thyroid disease (n = 6), sjogren syndrome (n = 4), rheumatoid arthritis (n = 4), systemic lupus erythematosus (n = 1), myasthenia gravis (n = 1), or abnormal autoantibodies without clinical features (n = 2). Compared with the AQP4-IgG-(À) group, the rate of co-existing autoimmune disorders was higher in the AQP4-IgG-(+) group (Table 1) .
Treatment and outcome
66 cases were treated with methylprednisolone boli (500 mg QD Â 3). After the therapy, the EDSS score of AQP4-IgG (+) group was 2.2 ± 1.3 and the AQP4-IgG (À) group was 1.6 ± 0.6, the difference was statistically significant (P <.05). 1 case was treated with nutrients with no improvement. The median duration of the 2 groups were 3.1 ± 3.6 years and 1.2 ± 2.9 years, respectively, which have significant difference (P = .04). The rate of AQP4-IgG (+) in the monophasic and recrudescent course patients was 28.6% and 71.4%, respectively, the difference is statistically significant (Table 1 ).
Discussion
NMOSD is an inflammatory, demyelinating syndrome of the CNS with the discrete, relapsing characters. Moreover, NMO-IgG, an autoantibody, especially attacks the AQP4 expression zone, especially the surrounding ventricular, which may induce corresponding clinical manifestations, such as ON or myelitis. [7] [8] [9] Population-based studies have described that 0.05 to 0.4 per Our study results suggest that the patients with seropositive antibody tend to have autoimmune disorders coexistence (17/49 vs 1/18), longer duration of symptoms (3.1 ± 3.6 vs 1.2 ± 2.9), poor prognosis (2.2 ± 1.3 vs 1.6 ± 0.6), and the patients with seropositive antibody tend to have a monophasic course (10/18 vs 14/49). Significant results are reported in bold (P <.05). MRI = magnetic resonance imaging, ON = optic neuritis.
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Medicine 100,000 patients are AQP4-IgG (+), and this accounts for half of the clinical diagnosis of people with NMOSD. [10, 11] An extensive literature showed that NMOSD may occur in any age, and in both sexes, but it has a postpubertal female preponderance. [1, 12] Patients with co-existing autoimmune disorders may strengthen confidence about an NMOSD diagnosis. Since NMOSD has a high recurrence rate, disability rate, and disease burden and there may exist clinical differences between seropositive and seronegative patients, it is important to have a correct recognition.
We compared the clinical features of patients with AQP4-IgG (+) (n = 49, 73.1%) and AQP4-IgG (À) (n= 18, 26.9%) who had a clinical diagnosis of NMOSD. [6] Our study results suggest that patients with seropositive antibody tended to have a postpubertal female preponderance, single part involvement (ON or myelitis), autoimmune disorders coexistence, longer duration of symptoms, poor prognosis and polyphasic course. Statistical analysis showed that these differences between the 2 groups were significant (P <.05), but there was no difference in onset age and MRI lesions between the 2 groups (P >.05).
However, this study has several limitations as follows. First, we used indirect immunofluorescence to detect only AQP4-IgG antibody without other methods and antibodies. Second, there is a lack of within-group comparison in this study, including ages and clinical sympotoms. Third, this study did not compare NMOSD with other demyelinating disease of CNS, such as MS and ADEM. Additionally, this study may have some limitation such as small sample sizes and short-term follow-up.
Compared with AQP4-IgG (+) group, patients with AQP4-IgG (À) are likely to have a better prognosis and a favorable monophasic course. This reveals that AQP4 antibody not only can distinguish NMOSD from other diseases, but also may help to predict the patients who are at risk of recurrent, and could guide decisions regarding diagnostic and therapeutic strategies. 
